Q3 2020 Presentation and report

Tromsø, Norway, 22 October 2020 – ArcticZymes Technologies (OSE: AZT) reported sales of NOK 30.8 million (22.5) and an EBITDA of NOK 10.1 million (0.8) for the third quarter of 2020. Underlying growth continues. Highlights from Q3 2020 Annual group sales exceed 100 MNOK for the first time Gross profit for the Group improved 65% to NOK 26.0 million (Q3 …

Invitation to Q3 2020 Presentation

ArcticZymes Technologies presents its report for the third quarter 2020 on Thursday, 22. October 2020 at 08.30 a.m. Due to the ongoing situation with spread of coronavirus, a number of measures are being implemented to prevent the spread of infection. These measures are being taken to safeguard the health and security of the Company’s shareholders, employees and other stakeholders, and …

ArcticZymes enters into agreement with Jiangsu Simcere Diagnostics for HL-SAN

ArcticZymes has entered into a supply and distribution agreement with Chinese precision medicine company Jiangsu Simcere Diagnostics. HL-SAN will be used in development and manufacturing of Simsere’s infectious disease metagenomic assays. In metagenomic sequencing, all DNA in the sample is sequenced. In clinical samples, the amount of DNA from the patient far outweighs the amount of DNA from pathogens. This …

Virus-X TV documentary

Euronews has made a TV documentary on the Horison2020 project “Virus-X” where ArcticZymes was one of the industrial partners. The TV documentary can be seen HERE   About Virus-X The project “Viral Metagenomics for Innovation Value” (Virus-X), was a large collaboration project between a total of 15 partners from European research institutes, universities and industry with a total budget of …